Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 2/20 | 0.37 |
| ▸ | USP14 | P54578 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 3/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473013 | 1.00 | KDM4E (0.41) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472872 | 1.00 | KDM4E (0.41) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472881 | 0.95 | KDM4E (0.41) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472657 | 0.95 | KDM4E (0.41) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472863 | 0.95 | KDM4E (0.41) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472932 | 0.95 | KDM4E (0.46) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472909 | 0.95 | KDM4E (0.46) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472888 | 0.95 | KDM4E (0.46) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472887 | 0.95 | KDM4E (0.46) | KDM4EATML3MBTL1G6PDUSP14 | |
| SCHEMBL21472682 | 0.93 | KDM4E (0.40) | KDM4EATML3MBTL1G6PDJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124521-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-09-21 | — | — | US | disclosed |
| US-20190315760-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMNITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124521-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CRY2, CCNT1 | KDM4E 2960/4885ATM 1582/4885L3MBTL1 958/4885 |
| US-20190315760-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMNITTING DEVICE INCLUDING THE SAME | CCNT1, CRY1, CCNT2 | KDM4E 3323/4885ATM 1356/4885L3MBTL1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.